Abstract
Objectives: In health, nitric oxide (NO) can be measured in high concentrations in the upper respiratory tract. It has been shown that nasal NO (nNO) is significantly lower in patients with sinonasal inflammation such as patients with Cystic Fibrosis (CF). In patients with CF treated with elexacaftor-tezacaftor-ivacaftor (ETI), clinical improvement of sinonasal inflammatory symptoms could be observed. We therefore hypothesised that nNO would increase in patients undergoing ETI treatment between a baseline measurement and after several months of treatment. Furthermore we are interested to see if nNO correlates with other parameters such as inflammatory markers, lung function and sweat chloride.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
